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Abstract 
 
Background  
Alterations  of  coagulation  profile  have  been  reported  in 
patients with β-thalassaemia major (β-TM).  
Method  
To investigate this in the paediatric population, we studied 
haemostatic  parameters  in  pre-transfusion  blood  samples 
from  50  non-splenectomised  transfusion-dependent 
children  with  β-TM  (mean  age  6±2.5  years)  and  in  blood 
from 25 healthy controls.  
Results  
Laboratory  evaluation  showed  thrombocytopenia  in  40%, 
prolongation  of  prothrombin  time  (PT)  in  12%  and 
prolongation  of  activated  partial  thromboplastin  time 
(APTT) in 6% of the patients. Mean values for PT, APTT and 
platelet count (PC) were all raised in the patient population 
compared with the controls. The alteration of coagulation 
status  was  significant  for  PT  (p value  <0.005)  and  APTT 
(p value  <0.0001).  However,  the  change  for  PC  was  not 
significant  (p value  >0.05).  No  significant  liner  correlation 
could be identified between PT, APTT,  PC of the patients 
and interval between transfusions (in days) or days  since 
last transfusion.  
Conclusion  
The  findings  from  this  study  suggest  that  a  subclinical 
haemorrhagic  tendency  exists  in  patients  with  β-TM  at  a 
very early age. The intrinsic pathway appears to be more 
affected than the extrinsic pathway. 
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What this study adds: 
1.  Paediatric  patients  with  β-thalassaemia  major  have  a 
subclinical haemorrhagic tendency. 
2. The intrinsic contact activation pathway is more affected 
in these patients than is the extrinsic tissue factor pathway. 
3. Chelation therapy in these patients may further alter the 
coagulation profile. 
 
Background 
Thalassaemia  syndromes  represent  one  of  the  most 
common  forms  of  hereditary  haemolytic  anaemia. 
Presently, over 250 million people worldwide are affected 
by thalassaemia and allied disorders. The frequency of β-
thalassaemia in India ranges from 3.5 to 15% in the general 
population, with nearly 10,000 children with β-thalassaemia 
major  (β-TM)  born  every  year.
1,2  Comprehensive 
thalassaemia care services have substantially improved life 
expectancy  and  quality  of  life  in  these  patients. 
Consequently, late effects of the treatment modalities, such 
as polytransfusion, splenectomy and chelation therapy are 
gradually becoming more apparent.  
 
The adverse effects on the  cardiovascular, endocrine and 
hepatic systems have been well studied. An emerging body 
of evidence has drawn attention to haemostatic alterations 
and  their  consequent  effects.  A  higher  incidence  of 
thromboembolic manifestations has been noted in patients 
with β-TM and the presence of haemostatic abnormalities 
suggest the existence of a chronic hypercoagulable state.
3–5 
These manifestations range from transient ischaemic attack, 
stroke, acute myocardial infarction, deep vein thrombosis to 
pulmonary  embolism.
3,6–8  Inadequate  transfusions,  a 
common problem  for thalassaemic patients in developing 
countries,  and  splenectomy,  a  standard  management 
modality, have both been implicated in the development of 
this hypercoagulable state.
9 There have also been reports of 
epistaxis  and  haematuria,  suggesting  a  haemorrhagic 
tendency  in  these  patients.
10–12  However,  most  of  these 
studies  were  performed  on  adult  or  young  adult 
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populations. Hence, this study was designed to investigate 
the situation in a cohort of paediatric patients. 
 
Method 
This  was  a  cross-sectional  laboratory  study  involving 
50 paediatric patients with β-TM and 25 suitable controls 
(healthy children attending a vaccination clinic, mean age 
3.3±1.9  years).  Transfusion-dependent  (requiring 
transfusions  at  intervals  of  at  least  15  days),  non-
splenectomised  children  below  10  years  of  age  who  had 
never  undergone  chelation  therapy  were  included  in  the 
study. Children with hepatitis B, C or HIV were excluded. 
The  rationale  behind  such  an  inclusion  criteria  was  that 
coagulation abnormalities have been found in adult patients 
and  children  who  have  had  splenectomy
7  and  who  were 
receiving  chelation  therapy.
12  Hence,  we  wanted  to 
investigate  this  problem  in  a  cohort  of  treatment-naive 
paediatric patients, who were as close to the natural history 
of the disease as possible. We chose a margin of at least 
15 days since the last transfusion in order to eliminate any 
confounding effects from a recent blood transfusion.  
 
We  used  the  cardinal  parameters  of  haemostasis—
prothrombin  time  (PT,  normal  11–16  s),  activated  partial 
thromboplastin  time  (APTT,  normal  26–40  s)  and  PC 
(platelet count normal 150–400×10
3 per µL) to investigate 
the coagulation profile. Blood was collected from patients 
(pre-transfusion  samples)  and  controls  in  sodium  citrate 
(3.2%) and EDTA vials (1.5 mg/mL of blood). An automated 
blood cell counter (Sysmex Hematology Analyzer KX-21) and 
coagulation  analyser  (Sysmex  CA-50)  were  used  to 
determine the PC, PT and APTT. Simple statistics (mean and 
standard deviation [SD]), Pearson’s coefficient of correlation 
and multiple hypothesis testing (at level α=0.05) were used 
in MatLab 7.1 to analyse the data. Informed consent was 
collected from the guardians of the patients in accordance 
with the Declaration of Helsinki. The study was approved by 
the  Indian  Council  of  Medical  Research  (Short  Term 
Studentship  program)  and  the  Institutional  Ethics 
Committee of the hospital. 
 
Results  
The mean age of the patients was 6±2.5 years (range 1.5–
10 years).  The  majority  (40%)  of  the  patients  required 
transfusions at intervals of 30 days (Figure 1). 
 
 
 
 
 
 
Figure 1: Proportion of patients grouped according to 
interval between transfusions  
 
There were significant differences in the PT and APTT values 
between the patients and controls (Table 1). 
 
Mean (± SD) 
for 
Patients  Controls  p value 
PT (s)  14±7  11±1  <0.005 
APTT (s)  31±5  26±2  <0.0001  
PC (×10
3/µL)  217±160  171±22  >0.05 
 
Table 1: Coagulation parameters in cases and controls 
(approximate whole number values have been presented) 
 
The percentage of patients  and controls with coagulation 
parameters outside the normal range are shown in Table 2. 
Note the percentage of patients with prolonged PT, APTT 
and thrombocytopenia. A substantial portion of the controls 
had PT, APTT values below normal range. 
 
Coagulation 
parameter 
values 
Percentage of 
patients 
Percentage of 
controls 
Above 
normal 
Below 
normal 
Above 
normal 
Below 
normal 
PT  12%  6%  0%  24% 
APTT  6%  0%  0%  48% 
PC  6%  40%  0%  12% 
 
Table  2:  Percentage  of  patients  and  controls  with 
coagulation parameters outside the normal range 
 
The  lack  of  linear  correlation  between  the  coagulation 
parameters  and  interval  between  transfusions  and  days 
since transfusion for the patients is shown in Table 3. 
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Correlation coefficient 
(r) between 
PT  APTT  Platelet 
Count 
Interval between 
transfusions (days) 
–0.1  –0.2  0.2 
Last transfusion (days 
back) 
0.1  –0.1  0 
 
Table 3: Correlation between the coagulation parameters 
and  interval  between  transfusions  and  days  since 
transfusion for the patients 
 
Discussion 
In  this  series  of  paediatric  patients  with  β-TM  who  had 
neither  had  splenectomy  or  chelation  therapy,  we  noted 
that 40% had thrombocytopenia.  The patients studied by 
Caocci  et  al  were  very  similar  to  our  population  (no 
splenectomy  or  chelation  therapy,  n=25)  and  had  normal 
PC.
13 Naithani et al, however, noted thrombocytopenia in a 
lower percentage (33.3%) of their paediatric patients (non-
splenectomised,  n=50),  but  these  patients  were  already 
undergoing chelation therapy.
12 So, if hypersplenism alone 
were  to  account  for  thrombocytopenia  in  these  patients, 
then those studied by Caocci et al would be expected to 
have  some  degree  of  thrombocytopenia  owing  to 
hypersplenism.
13  Similarly, the patients studied by Naithani 
et  al  would  be  expected  to  have  even  more 
thrombocytopenia  owing  to  hypersplenism  and  chelation 
therapy,  which  can  itself  cause  thrombocytopenia.  Thus 
hypersplenism  alone  does  not  account  for 
thrombocytopenia  in  our  patients.  Hence,  a  subclinical 
chronic  consumption  state  may  be  responsible  for  the 
thrombocytopenia  seen  in  our  patients.  This  subclinical 
chronic  consumption  state  could  also  explain  the  relative 
prolongation of PT and APTT seen in our patients compared 
with the controls. Although the PT, APTT and PC values for 
the patients in this  study were  mostly within the normal 
range, the mean values for these parameters were all raised 
and these changes were significant for PT (p value <0.005) 
and highly significant (p value<0.0001) for APTT. However, 
the change for PC was not significant (p value >0.05). This 
shows  that  a  subclinical  alteration  in  coagulation  profile 
exists  in  polytransfused  non-splenectomised  paediatric 
patients  with  β-TM  and  that  this  alteration  may  be 
attributed to dysfunction of the coagulation cascade rather 
than  platelet  numbers.  Platelet  function  may  also  have  a 
role, but this could not be evaluated in our study.  
 
Such significant results for PT and APTT draws our attention 
to  another  fact:  that  24%  of  otherwise  normal  control 
subjects  had  PT  values  below  the  normal  range,  while  a 
staggering 48% of the same controls had APTT values below 
the normal range. We also noted a more significant change 
in p value for APTT (p<0.0001) than that for change in PT 
(p<0.005).  APTT  is  the  performance  indicator  for  the 
intrinsic  (or  contact  activation)  pathway  and  the  final 
common pathways whereas PT measures the same for the 
extrinsic  (or  tissue  factor)  pathways  and  final  common 
pathways.  Hence,  a  more  significant  change  for  APPT 
apparently suggests that the intrinsic pathway may be more 
consistently  affected  than  the  extrinsic  pathways.  Other 
authors  have  also  supported  this  hypothesis  of  chronic 
activation  of  the  intrinsic  coagulation  cascade  in  these 
patients  owing  to  the  effect  of  multiple  transfusions  and 
haemolysates.
13,14 
 
Table  4  shows  some  pertinent  differences  between  our 
findings  and  those  by  Naithani  et  al,
12  who  had  a  very 
comparable  patient  population.  However,  all  of  their 
patients were undergoing chelation therapy. None of our 
patients had ever received chelation therapy; hence, these 
differences suggested that chelation therapy might confer 
increased risk for haemostatic alterations.  
 
Findings by  Naithani et al  This study  
Thrombocytopenia 
seen in 
33.3% of 
patients 
40% of 
patients 
Prolongation of PT 
seen in 
40.7% of 
patients 
12% of 
patients 
Prolongation of APTT 
seen in 
46.3% of 
patients 
6% of patients 
 
Table  4:  Differences  between  our  findings  and  those  by 
Naithani et al 
 
We had initially hypothesised that patients requiring more 
frequent transfusions have more haemolysis and thus may 
have a more deranged coagulation profile owing to more 
pronounced hypersplenism and the effect of haemolysates. 
However this hypothesis was could not be supported due to 
the non-significant correlation coefficients (see Table 3). It 
also  showed  that  no  appreciable  pattern  of  linear 
correlation  exists  between  PT,  APTT  and  PC  values  and 
interval between transfusions (in days) and days since last 
transfusion. 
 
Possible  explanations  for  the  absence  of  thrombotic 
tendency  in  our  population  might  be  young  age  and  the 
presence of the spleen, which clears the damaged red blood 
cells. It may be possible that thrombotic tendency develops 
with increasing age, as noted by other studies, which were 
conducted in adults or young adults.
6,7,9 Splenectomy has 
been  implicated  in  the  development  of  thrombotic  state 
owing to the presence of more damaged red blood cells in 
the  circulation.
7,9  Other  studies  have  noted  decreases  in  Australasian Medical Journal [AMJ 2012, 5, 2, 152-155] 
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both thrombophilic and anti-thrombotic proteins in these 
patients  as  a  consequence  of  liver  damage;  hence,  the 
clinical  picture  depends  on  the  fine  balance  of  the 
contributinfg factors.
15 
 
Our  study  aimed  to  assess  the  coagulation  profile  of 
children with β-TM through investigations that are relevant 
in everyday clinical practice. Hence, advanced parameters 
of haemostasis such as platelet function, protein C and S, 
antithrombin-III, and D-dimers  were beyond  the  scope of 
our study. These, however, may be used to elucidate the 
exact mechanisms of this defect, which still remains unclear. 
 
Conclusion 
It appears that a subclinical haemorrhagic tendency exists in 
patients with β-TM at a very early age. The intrinsic pathway 
appears to be more affected than the extrinsic pathway.  
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